Journal of Natural Remedies

Open Access Open Access  Restricted Access Subscription Access

Assessment of Anxiolytic Activity of Brahmi (Bacopa monnieri) in Zebrafish Model System


Affiliations
1 Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India
2 Sansriti Foundation, Delhi - 110016, India
 

The increasing prevalence of anxiety and stress-related disorders has made it a leading contributor to the global health burden. The present treatment options have severe side effects and show remission on discontinuation of the medication. Hence, there is an urgent need to explore safer alternative treatments for long-term usage with minimum toxicity. The medicinal plant Brahmi (Bacopa monnieri) has been used in Indian traditional medicine as a neural tonic for centuries. The present study aimed to study the toxicity and anxiolytic activity of Brahmi using the zebrafish model system. The toxicity assays determined the minimum effective concentration of Brahmi to be 0.01%. In addition, behavioral assays such as thigmotaxis and scototaxis and endocrine assays such as the measurement of cortisol levels in stressed zebrafish larvae were performed. Zebrafish embryos exposed to 0.2% Brahmi up to seven days post fertilization (dpf) did not show any developmental toxicity. Behavioral and endocrine assays were performed on 5dpf zebrafish larvae treated with 0.01% Brahmi extract. Our studies show that Brahmi significantly reduced thigmotaxis (wall hugging) and scototaxis behavior in zebrafish larvae exposed to osmotic stress as compared to untreated stressed larvae. Stress activates the hypothalamic-pituitary-interrenal axis and stimulates the release of cortisol in zebrafish larvae. Whole body cortisol assay has shown that Brahmi significantly reduced the stress-induced release of cortisol in zebrafish larvae. Our studies report that Brahmi mitigates the stress response in zebrafish larvae and has minimum toxicity. This suggests that Brahmi may be a safe option for long term management of stress.

Keywords

Cortisol, HPI Axis, Scototaxis, Stress, Thigmotaxis.
Font Size

User

Notifications
JOURNAL COVERS
  

  • Collaborators C-MD. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312):1700-12. https://doi.org/10.1016/S0140-6736(21)02143-7

  • WHO. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. 2022 [Available from: https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide]

  • Rogers AH, Wieman ST, Baker AT. Anxiety comorbidities: Mood disorders, substance disorders, and chronic mental illness. Bui E, Charney ME, Baker AW, editors: Humana / Springer Nature; 2020; 77-103. https://doi.org/10.1007/978-3-030-30687-8_5

  • Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017; 19(2):93-107. https://doi.org/10.31887/DCNS.2017.19.2/bbandelow

  • Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020. https://doi.org/10.3389/fpsyt.2020.595584

  • Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry. 1987; 48:12-6. PMID: 2891684.

  • Medicines CoSo. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and reuptake inhibitors (SNRIs): use and safety. Medicines and Healthcare products Regulatory Agency (MHRA). 2014. [Available at: https://www.gov.uk/government/publications/ssris-and-snris-use-and-safety/selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-and-noradrenaline-reuptake inhibitors-snris-use and-safety].

  • George TT, Tripp J. Alprazolam: StatPearls Publishing. 2022. [Available from: https://www.ncbi.nlm.nih.gov/books/NBK538165/].

  • Parsaik AK, Mascarenhas SS, Khosh-Chashm D, Hashmi A, John V, Okusaga O, et al. Mortality associated with anxiolytic and hypnotic drugs-A systematic review and meta-analysis. Aust N Z J Psychiatry. 2016; 50(6):520-33. https://doi.org/10.1177/0004867415616695

  • Ezzat SM, Jeevanandam J, Egbuna C, Kumar S, Ifemeje JC. Phytochemistry: An in-silico and in-vitro Update. Kumar S, Egbuna C, editors. 2019. Phytochemistry: An in-silico and in-vitro Update. Springer, Singapore. https://doi.org/10.1007/978-981-13-6920-9_1

  • Basu N, Rastogi R, Dhar ML. Chemical examination of Bacopa mienniera wettst: part III-bacoside B. Ind J Chem. 1967; 5:84-95.

  • Bhattacharya SK, Ghosal S. Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine. 1998; 5:77-82. https://doi.org/10.1016/S0944-7113(98)80001-9

  • Chowdhuri DK, Parmar D, Kakkar P, Shukla R, Seth PK, Srimal RC. Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytother Res. 2002; 16(7):639-45. https://doi.org/10.1002/ptr.1023

  • Mannan M. Anxiolytic Effects of the Methanolic Extract of Bacopa monniera in Mice. Pharmacol. Pharm. 2019; 10:298-308. https://doi.org/10.4236/pp.2019.106024

  • Singh HK, Shanker G, Patnaik GK. Neuropharmacological and anti-stress effects of bacosides: A memory enhancer. Ind J Pharmacol. 1996; 28:47

  • Sheikh N, Ahmad A, Siripurapu KB, Kuchibhotla VK, Singh S, Palit G. Effect of Bacopa monniera on stress-induced changes in plasma corticosterone and brain monoamines in rats. J Ethnopharmacol. 2007; 111(3):671-6. https://doi.org/10.1016/j.jep.2007.01.025

  • Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013; 496(7446):498-503. https://doi.org/10.1038/nature12111

  • OECD guidelines for the testing of chemicals, Fish Embryo Acute Toxicity (FET) Test. OECD. 2013. https://doi.org/10.1787/9789264203709-en

  • Stewart AM, Braubach O, Spitsbergen J, Gerlai R, Kalueff AV. Zebrafish models for translational neuroscience research: from tank to bedside. Trends Neurosci. 2014; 37(5):264-78. https://doi.org/10.1016/j.tins.2014.02.011

  • Kalueff AV, Gebhardt M, Stewart AM, Cachat JM, Brimmer M, Chawla JS, et al. Towards a comprehensive catalog of zebrafish behavior 1.0 and beyond. Zebrafish. 2013; 10:70-86. https://doi.org/10.1089/zeb.2012.0861

  • McCarty R. Learning about stress: neural, endocrine and behavioral adaptations. Stress. 2016; 19(5):449-75. https://doi.org/10.1080/10253890.2016.1192120

  • Demin KA, Taranov AS, Ilyin NP, Lakstygal AM, Volgin AD, de Abreu MS, et al. Understanding neurobehavioral effects of acute and chronic stress in zebrafish. Stress. 2021; 24(1):1-18. https://doi.org/10.1080/10253890.2020.17249 48

  • de Abreu MS, Demin KA, Giacomini A, Amstislavskaya TG, Strekalova T, Maslov GO, et al. Understanding how stress responses and stress-related behaviors have evolved in zebrafish and mammals. Neurobiol Stress. 2021; 15:100405. https://doi.org/10.1016/j.ynstr.2021.100405

  • Gupta R, Ranjan S, Yadav A, Verma B, Malhotra K, Madan M, et al. Toxic Effects of Food Colorants Erythrosine and Tartrazine on Zebrafish Embryo Development. Curr Res Nutr Food Sci. 2019; 7(3). https://doi.org/10.12944/CRNFSJ.7.3.26

  • Schnorr SJ, Steenbergen PJ, Richardson MK, Champagne DL. Measuring thigmotaxis in larval zebrafish. Behav Brain Res. 2012; 228(2):367-74. https://doi.org/10.1016/j.bbr.2011.12.016

  • Clark KJ, Boczek NJ, Ekker SC. Stressing zebrafish for behavioral genetics. Rev Neurosci. 2011; 22(1):49-62. https://doi.org/10.1515/rns.2011.007

  • Bai Y, Liu H, Huang B, et al. Identification of environmental stressors and validation of light preference as a measure of anxiety in larval zebrafish. BMC Neurosci. 2016; 17(63). https://doi.org/10.1186/s12868-016-0298-z

  • Yeh CM, Glock M, Ryu S. An optimized whole-body cortisol quantification method for assessing stress levels in larval zebrafish. PLoS One. 2013; 8(11):e79406. https://doi.org/10.1371/journal.pone.0079406

  • Brimson JM, Brimson S, Prasanth MI, Thitilertdecha P, Malar DS, Tencomnao T. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. Sci Rep. 2021; 11(1):596. https://doi.org/10.1038/s41598-020-80045-2

  • Sireeratawong S, Jaijoy K, Khonsung P, Lertprasertsuk N, Ingkaninan K. Acute and chronic toxicities of Bacopa monnieri extract in Sprague-Dawley rats. BMC Complement Altern Med. 2016; 16:249. https://doi.org/10.1186/s12906-016-1236-4

  • Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic Bacopa monniera Linn. (Brahmi) Indian J Pharmacol. 1997; 29:359-65. https://doi.org/10.1089/rej.2013.1431.

  • Nathan PJ, Clarke J, Lloyd J, Hutchison CW, Downey L, Stough C. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol. 2001; 16(4):345-51. https://doi.org/10.1002/hup.306

  • Basnet RM, Zizioli D, Taweedet S, Finazzi D, Memo M. Zebrafish Larvae as a Behavioral Model in Neuropharmacology. Biomedicines. 2019; 7(1). https://doi.org/10.3390/biomedicines7010023

  • Wendelaar Bonga SE. The stress response in fish. Physiol Rev. 1997; 77(3):591-625. https://doi.org/10.1152/phys-rev.1997.77.3.59


Abstract Views: 137

PDF Views: 69




  • Assessment of Anxiolytic Activity of Brahmi (Bacopa monnieri) in Zebrafish Model System

Abstract Views: 137  |  PDF Views: 69

Authors

Padmshree Mudgal
Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India
Radhika Gupta
Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India
Adita Joshi
Sansriti Foundation, Delhi - 110016, India
Chandhana Prakash
Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India
Kajal Gupta
Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India
Ritika Sachdeva
Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India
Niharika Joshi
Department of Biochemistry, Daulat Ram College, University of Delhi, Delhi - 110007, India

Abstract


The increasing prevalence of anxiety and stress-related disorders has made it a leading contributor to the global health burden. The present treatment options have severe side effects and show remission on discontinuation of the medication. Hence, there is an urgent need to explore safer alternative treatments for long-term usage with minimum toxicity. The medicinal plant Brahmi (Bacopa monnieri) has been used in Indian traditional medicine as a neural tonic for centuries. The present study aimed to study the toxicity and anxiolytic activity of Brahmi using the zebrafish model system. The toxicity assays determined the minimum effective concentration of Brahmi to be 0.01%. In addition, behavioral assays such as thigmotaxis and scototaxis and endocrine assays such as the measurement of cortisol levels in stressed zebrafish larvae were performed. Zebrafish embryos exposed to 0.2% Brahmi up to seven days post fertilization (dpf) did not show any developmental toxicity. Behavioral and endocrine assays were performed on 5dpf zebrafish larvae treated with 0.01% Brahmi extract. Our studies show that Brahmi significantly reduced thigmotaxis (wall hugging) and scototaxis behavior in zebrafish larvae exposed to osmotic stress as compared to untreated stressed larvae. Stress activates the hypothalamic-pituitary-interrenal axis and stimulates the release of cortisol in zebrafish larvae. Whole body cortisol assay has shown that Brahmi significantly reduced the stress-induced release of cortisol in zebrafish larvae. Our studies report that Brahmi mitigates the stress response in zebrafish larvae and has minimum toxicity. This suggests that Brahmi may be a safe option for long term management of stress.

Keywords


Cortisol, HPI Axis, Scototaxis, Stress, Thigmotaxis.

References





DOI: https://doi.org/10.18311/jnr%2F2023%2F31362